Cited by 124Antifungal resistance and susceptibilityFungal and yeast genetics researchBacterial biofilms and quorum sensing

A novel small molecule inhibitor of Candida albicans biofilm formation, filamentation and virulence with low potential for the development of resistance

Open access
Pierce, Christopher G, Chaturvedi, Ashok K, Lazzell, Anna L, Powell, Alexander T, Saville, Stephen P, McHardy, Stanton F, Lopez-Ribot, Jose L·2015·npj Biofilms and Microbiomes

Abstract

Background/Objectives: Candida albicans is the principal causative agent of candidiasis, the most common fungal infection in humans. Candidiasis represents the third-to-fourth most frequent nosocomial infection worldwide, as this normal commensal of humans causes opportunistic infections in an expanding population of immune- and medically compromised patients. These infections are frequently associated with biofilm formation, which complicates treatment and contributes to unacceptably high mortality rates. Methods: To address the pressing need for new antifungals, we have performed a high-content screen of 20,000 small molecules in a chemical library (NOVACore) to identify compounds that inhibit C. albicans biofilm formation, and conducted a series of follow-up studies to examine the in vitro and in vivo activity of the identified compounds. Results: The screen identified a novel series of diazaspiro-decane structural analogs that were largely represented among the bioactive compounds. Characterization of the leading compound from this series indicated that it inhibits processes associated with C. albicans virulence, most notably biofilm formation and filamentation, without having an effect on overall growth or eliciting resistance. This compound demonstrated in vivo activity in clinically relevant murine models of both invasive and oral candidiasis and as such represents a promising lead for antifungal drug development. Furthermore, these results provide proof of concept for the implementation of antivirulence approaches against C. albicans and other fungal infections that would be less likely to foster the emergence of resistance.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/npjbiofilms.2015.12

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Screening of chemical libraries identified diazaspiro-decane structural analogs (Pierce et al.) and compounds with a biaryl amide core (Romo et al.) as inhibitors of C. albicans biofilm formation.

    “Pierce et al. reported on the identification of a new series of diazaspiro-decane structural analogs which were largely represented among the bioactive compounds [51]; whereas as reported in Romo et al. the two main hits belonged to a novel series of bioactive compounds with a common biaryl amide core structure [[52], [53], [54]].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Pierce, C. G., Chaturvedi, A. K., Lazzell, A. L., Powell, A. T., Saville, S. P., McHardy, S. F., & Lopez-Ribot, J. L.
Affiliations
The University of Texas at San Antonio (US)
Corresponding author
Lopez-Ribot, Jose L
Venue
npj Biofilms and Microbiomes
Published
2015-08-12
Volume
1
Issue
1
ISSN
2055-5008 (ISSN-L)
OpenAlex
W2419164965
Cited by
124
References
50
Citations by year
2026: 5 · 2025: 7 · 2024: 6 · 2023: 9 · 2022: 14 · 2021: 10 · 2020: 15 · 2019: 15 · 2018: 15 · 2017: 15 · 2016: 13
FWCI
11.18
Type
journal article
Language
en
Open access
Locations
  • npj Biofilms and Microbiomes (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • U.S. Department of Defense (W911NF1110136)
  • American Heart Association (11PRE5300004)
  • National Institute of Allergy and Infectious Diseases (R01AI063256)
  • National Institute of Dental and Craniofacial Research (R21DE017294, R01DE023510)
  • National Institute on Minority Health and Health Disparities (G12MD007591)
  • Army Research Office (W911NF-11-1-0136, W911NF, W911NF-11)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bacterial biofilms and quorum sensing
Keywords
Candida albicans, candidiasis, biofilm formation, filamentation, fungal virulence, antifungal drug development, small molecule inhibitors, high-content screening, anti-virulence strategies, antifungal resistance, oral candidiasis, invasive candidiasis, mouse infection model

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review